Magnesium-serinate compound and use thereof
AssigneeAstrogen, Inc.
InventorsSu-Kyeong Hwang, Min Yong Lee, Min Sook Seo, Do Youn Jun, Min Joo Kim, Young Ho Kim, Young Kyoung Jo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like.
Claims7
A compound of Serine-Mg-Serine or a pharmaceutically acceptable salt, solvate, hydrate or isomer of the compound
- wherein the compound has a peak formed at 800 to 1400 cm−1 and lacks a peak formed at 2100 cm−1 in Fourier transform infrared analysis:
- wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
- wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum;
- and
- wherein, for the 1H and 13C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D2O at 298 K.
A pharmaceutical composition for preventing or treating central nervous system diseases, the pharmaceutical composition containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
- wherein the compound has a peak formed at 800 to 1400 cm−1 and lacks a peak formed at 2100 cm−1 in Fourier transform infrared analysis:
- wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
- wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum;
- and
- wherein, for the 1H and 13C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D2O at 298 K.
A health functional food for preventing or alleviating central nervous system diseases, the health functional food containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
- wherein the compound has a peak formed at 800 to 1400 cm−1 and lacks a peak formed at 2100 cm−1 in Fourier transform infrared analysis:
- wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
- wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum;
- and
- wherein, for the 1H and 13C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D2O at 298 K.
A feed additive composition comprising a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof as an active ingredient,
- wherein the compound has a peak formed at 800 to 1400 cm−1 and lacks a peak formed at 2100 cm−1 in Fourier transform infrared analysis:
- wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
- wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum;
- and
- wherein, for the 1H and 13C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D2O at 298 K.
A reagent composition for inhibiting neuronal cell death, the reagent composition containing a compound of Serine-Mg-Serine or a pharmaceutically acceptable salt thereof,
- wherein the compound has a peak formed at 800 to 1400 cm−1 and lacks a peak formed at 2100 cm−1 in Fourier transform infrared analysis:
- wherein the compound exhibits a 1H NMR peak located at 0.2 ppm upfield from the α-carbon peak and 0.4 to 0.5 ppm upfield from the β-carbon peak of L-serine;
- wherein the carbonyl carbon (C═O) resonance of the compound is shifted downfield by 5.556 to 7.509 ppm relative to that of L-serine, and the β-carbon (C—O) resonance is shifted downfield by 2.548 to 3.725 ppm in the 13C NMR spectrum;
- and
- wherein, for the 1H and 13C NMR measurements, 100 mg of the compound is dissolved in 0.7 mL of D2O at 298 K.
Dependencies are inferred from the claim text.